The study is of Ellen of Ellen K

Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine in combination with cytarabineVION Pharmaceuticals announced the start of an investigator sponsored Phase I / II study of its lead anticancer agent Cloretazine in combination with cytarabine in elderly myelodysplastic patients with previously untreated acute myeloid leukemia and high-risk syndromes . The study is of Ellen of Ellen K . Ritchie, MD The Weill Cornell Medical College in New York City. Co – investigators for the study are Eric Feldman, MD and Gail Roboz, MD – The objectives of the study are : define the maximum tolerated dose of Cloretazine when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and the combination further to evaluate safety and efficacy in a larger cohort of patients. Cloretazine 60 minute a 30 – 60 minute infusion on day 1 about 3-4 hours after the start of infusion cytarabine. Conditions, is a continuous infusion of a continuous infusion of 100 mg/m2 for 7 days. In the phase I part of the study, dose escalation in cohorts at least 3 at least 3 patients and the maximum tolerated dose used in the Phase I segment in the Phase II segment of the study identified. Ann Cahill, Vice President, Clinical Development, said, ‘It is important for us to continue Cloretazine in combination studies with different doses and schedules of cytarabine, the drug most often used in the treatment of AML Moreover, we want Moreover, we want Cloretazine are evaluated in a large group of elderly patients as currently being evaluated in our pivotal trial of Cloretazine monotherapy Cahill conclusion. ‘Cloretazine has activity activity in AML and MDS justifies further studies in the treatment of these devastating conditions, both as monotherapy and in combination with other therapies, ‘.

This press release contains forward-looking statements. Such statements are subject to certain risk factors which lead Vion Vion plans or results to differ materially from the expected results differ, including potential inability Vion is in order of approval for its products, particularly Cloretazine , delayed or unfavorable results may receive drugs studies, the possibility that the positive results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy in subsequent clinical trials, not intend to the need for additional research and testing, the inability to product manufacturing, the potential inability to external funding sources to continue the operation, access the inability capital and financing sat on favorable terms, continued operating losses and the inability to operations as a result, and a variety of other risks included from time to time in Vion ‘s filings with the Securities and Exchange Commission, including but not limited to the risks associated with the forward-looking statements in Item 1A, Risk Factors in Vion ‘s Form 10 – K for the year ended 31 December 2007 limited. In particular, there may be no guarantee of the results of any of Vion clinical studies that each of these studies is to continue the accrual, or that any of these studies is not adjusted, modified, delayed or discontinued altogether. Except in special cases, in which a duty to update arises under law when prior disclosure is considerably misleading light of subsequent events, Vion does not not intend to Pharmaceuticals, statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Fair view Health Service and University of Minnesota has a gift from announces $ 50 million Caroline Amplatz, announced that their father, a former professor at the University of honoring and medical devices pioneers Kurt Amplatz, MD Add recognition of the gift, the new plant by the name University of Minnesota Amplatz Children’s Hospital to be. The hospital which broke floor last summer, being in the schedule to show by mid 2011.